Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Albendazole for Neurocysticercosis
NCT00283699Phase 3
Key facts
- Status
- Completed
- Start
- Feb 2001
- Primary completion
- Feb 2005
- Countries
- 1
- Sponsor
- Columbia University
- Modality
- Small Molecules
- Drugs
- albendazole
- Conditions
- neurocysticercosis (NCC)
01
Overview
Phase 3, randomised, double-blind trial in neurocysticercosis (NCC) comparing Albendazole + Symptomatic Therapy with Placebo + Symptomatic Therapy (2 arms). Primary endpoint: Cyst freedom at 1 year. Started Feb 2001; status: completed.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Albendazole + Symptomatic Therapy
Albendazole (15 mg/kg/day or 800 mg) + prednisolone + standard symptomatic therapy
Placebo + Symptomatic Therapy
Placebo + prednisolone + standard symptomatic therapy
03
Who it enrols
Patients with new-onset neurocysticercosis symptoms within 2 months and active/transitional cysts on imaging. Excludes pregnant patients, those with only calcifications, specific concurrent conditions (papilledema, active tuberculosis, syphilis, ocular cysticercosis, active gastric ulcers), and recent use of anthelmintic drugs or steroids.
04
Endpoints
Primary
Cyst freedom
Secondary
Cyst reduction
Seizure freedom
Beyond the preview
Go deeper on NCT00283699.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00283699.